An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
1 Heart Failure and Structural Heart Disease Research Unit, Cardiovascular Analytics Group, Hong Kong, Hong Kong SAR, China.
2 Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
3 Department of Internal Medicine and Cardiology, Theodor Burghele Clinical Hospital, Bucharest, Romania.
4 Heart Failure and Structural Cardiology Division, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
5 Onassis Cardiac Surgery Center, Athens, Greece.
6 Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China.
1 Heart Failure and Structural Heart Disease Research Unit, Cardiovascular Analytics Group, Hong Kong, Hong Kong SAR, China.
2 Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
3 Department of Internal Medicine and Cardiology, Theodor Burghele Clinical Hospital, Bucharest, Romania.
4 Heart Failure and Structural Cardiology Division, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
5 Onassis Cardiac Surgery Center, Athens, Greece.
6 Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China.
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Comment on
Editorial on the Research Topic Novel phenotyping and risk stratification strategies for heart failure
References
Roger VL. Epidemiology of heart failure. Circ Res. (2021) 128:1421–34. 10.1161/CIRCRESAHA.121.318172
-
DOI
-
PubMed
Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. (2020) 22:1342–56. 10.1002/ejhf.1858
-
DOI
-
PMC
-
PubMed
Wintrich J, Kindermann I, Ukena C, Selejan S, Werner C, Maack C, et al. Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. Clin Res Cardiol. (2020) 109:1079–98. 10.1007/s00392-020-01633-w
-
DOI
-
PMC
-
PubMed
Lakhani I, Wong MV, Hung JKF, Gong M, Waleed K, Bin Xia Y, et al. Diagnostic and prognostic value of serum C-reactive protein in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart Fail Rev. (2021) 26:1141–50. 10.1007/s10741-020-09927-x
-
DOI
-
PMC
-
PubMed
Wang W, Mu G, Liu C, Xie J, Zhang H, Zhang X, et al. A novel three-dimensional and tissue doppler echocardiographic index for diagnosing and prognosticating heart failure with preserved ejection fraction. Front Cardiovasc Med. (2022) 9:822314. 10.3389/fcvm.2022.822314
-
DOI
-
PMC
-
PubMed